Cargando…
The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function
SIMPLE SUMMARY: New-FP is a regimen of hepatic arterial infusion chemotherapy for hepatocellular carcinoma (HCC). In the study, the regimen significantly prolonged the survival of patients with major portal vein tumor thrombus-HCC. ABSTRACT: Background: Systemic treatments are recommended for advanc...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562659/ https://www.ncbi.nlm.nih.gov/pubmed/36230795 http://dx.doi.org/10.3390/cancers14194873 |
_version_ | 1784808223819169792 |
---|---|
author | Iwamoto, Hideki Niizeki, Takashi Nagamatsu, Hiroaki Ueshima, Kazuomi Tani, Joji Kuzuya, Teiji Kasai, Kazuhiro Kooka, Youhei Hiraoka, Atsushi Sugimoto, Rie Yonezawa, Takehiro Tanaka, Satoshi Deguchi, Akihiro Shimose, Shigeo Shirono, Tomotake Sakai, Miwa Suzuki, Hiroyuki Moriyama, Etsuko Koga, Hironori Torimura, Takuji Kawaguchi, Takumi |
author_facet | Iwamoto, Hideki Niizeki, Takashi Nagamatsu, Hiroaki Ueshima, Kazuomi Tani, Joji Kuzuya, Teiji Kasai, Kazuhiro Kooka, Youhei Hiraoka, Atsushi Sugimoto, Rie Yonezawa, Takehiro Tanaka, Satoshi Deguchi, Akihiro Shimose, Shigeo Shirono, Tomotake Sakai, Miwa Suzuki, Hiroyuki Moriyama, Etsuko Koga, Hironori Torimura, Takuji Kawaguchi, Takumi |
author_sort | Iwamoto, Hideki |
collection | PubMed |
description | SIMPLE SUMMARY: New-FP is a regimen of hepatic arterial infusion chemotherapy for hepatocellular carcinoma (HCC). In the study, the regimen significantly prolonged the survival of patients with major portal vein tumor thrombus-HCC. ABSTRACT: Background: Systemic treatments are recommended for advanced hepatocellular carcinoma (HCC) in preserved liver function. However, their effects are unsatisfactory in some tumor conditions, particularly macrovascular invasion (MVI) including major portal vein tumor thrombus (PVTT). We compared the efficacy of hepatic arterial infusion chemotherapy (HAIC) regimens New-FP and sorafenib for various tumor conditions in preserved liver function. Methods: We retrospectively collected the data of 1709 patients with HCC who were treated with New-FP or sorafenib. Survival was assessed after propensity score matching. Subgroup analyses were conducted: cohort 1 (no MVI or extrahepatic spread (EHS)), cohort 2 (MVI only), cohort 3 (EHS only), cohort 4 (MVI and EHS), and cohort 5 (major PVTT). Results: The New-FP group had a longer median survival time (MST) than the sorafenib in the whole analysis (18 vs. 9 months; p < 0.0001). New-FP demonstrated a longer MST compared with sorafenib in cohort 2 and cohort 4. In cohort 5, the MST of the New-FP group was 16 months, while that of sorafenib was 6 months (p < 0.0001). For major PVTT-HCC, the response rate of New-FP was 73.0%. The MST of patients who achieved complete response with New-FP was 59 months. Conclusions: HAIC using New-FP is promising for patients with MVI- and major PVTT-HCC in preserved liver function. |
format | Online Article Text |
id | pubmed-9562659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95626592022-10-15 The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function Iwamoto, Hideki Niizeki, Takashi Nagamatsu, Hiroaki Ueshima, Kazuomi Tani, Joji Kuzuya, Teiji Kasai, Kazuhiro Kooka, Youhei Hiraoka, Atsushi Sugimoto, Rie Yonezawa, Takehiro Tanaka, Satoshi Deguchi, Akihiro Shimose, Shigeo Shirono, Tomotake Sakai, Miwa Suzuki, Hiroyuki Moriyama, Etsuko Koga, Hironori Torimura, Takuji Kawaguchi, Takumi Cancers (Basel) Article SIMPLE SUMMARY: New-FP is a regimen of hepatic arterial infusion chemotherapy for hepatocellular carcinoma (HCC). In the study, the regimen significantly prolonged the survival of patients with major portal vein tumor thrombus-HCC. ABSTRACT: Background: Systemic treatments are recommended for advanced hepatocellular carcinoma (HCC) in preserved liver function. However, their effects are unsatisfactory in some tumor conditions, particularly macrovascular invasion (MVI) including major portal vein tumor thrombus (PVTT). We compared the efficacy of hepatic arterial infusion chemotherapy (HAIC) regimens New-FP and sorafenib for various tumor conditions in preserved liver function. Methods: We retrospectively collected the data of 1709 patients with HCC who were treated with New-FP or sorafenib. Survival was assessed after propensity score matching. Subgroup analyses were conducted: cohort 1 (no MVI or extrahepatic spread (EHS)), cohort 2 (MVI only), cohort 3 (EHS only), cohort 4 (MVI and EHS), and cohort 5 (major PVTT). Results: The New-FP group had a longer median survival time (MST) than the sorafenib in the whole analysis (18 vs. 9 months; p < 0.0001). New-FP demonstrated a longer MST compared with sorafenib in cohort 2 and cohort 4. In cohort 5, the MST of the New-FP group was 16 months, while that of sorafenib was 6 months (p < 0.0001). For major PVTT-HCC, the response rate of New-FP was 73.0%. The MST of patients who achieved complete response with New-FP was 59 months. Conclusions: HAIC using New-FP is promising for patients with MVI- and major PVTT-HCC in preserved liver function. MDPI 2022-10-05 /pmc/articles/PMC9562659/ /pubmed/36230795 http://dx.doi.org/10.3390/cancers14194873 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Iwamoto, Hideki Niizeki, Takashi Nagamatsu, Hiroaki Ueshima, Kazuomi Tani, Joji Kuzuya, Teiji Kasai, Kazuhiro Kooka, Youhei Hiraoka, Atsushi Sugimoto, Rie Yonezawa, Takehiro Tanaka, Satoshi Deguchi, Akihiro Shimose, Shigeo Shirono, Tomotake Sakai, Miwa Suzuki, Hiroyuki Moriyama, Etsuko Koga, Hironori Torimura, Takuji Kawaguchi, Takumi The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function |
title | The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function |
title_full | The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function |
title_fullStr | The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function |
title_full_unstemmed | The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function |
title_short | The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function |
title_sort | clinical impact of hepatic arterial infusion chemotherapy new-fp for hepatocellular carcinoma with preserved liver function |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562659/ https://www.ncbi.nlm.nih.gov/pubmed/36230795 http://dx.doi.org/10.3390/cancers14194873 |
work_keys_str_mv | AT iwamotohideki theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT niizekitakashi theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT nagamatsuhiroaki theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT ueshimakazuomi theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT tanijoji theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT kuzuyateiji theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT kasaikazuhiro theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT kookayouhei theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT hiraokaatsushi theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT sugimotorie theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT yonezawatakehiro theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT tanakasatoshi theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT deguchiakihiro theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT shimoseshigeo theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT shironotomotake theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT sakaimiwa theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT suzukihiroyuki theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT moriyamaetsuko theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT kogahironori theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT torimuratakuji theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT kawaguchitakumi theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT theclinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT iwamotohideki clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT niizekitakashi clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT nagamatsuhiroaki clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT ueshimakazuomi clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT tanijoji clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT kuzuyateiji clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT kasaikazuhiro clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT kookayouhei clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT hiraokaatsushi clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT sugimotorie clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT yonezawatakehiro clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT tanakasatoshi clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT deguchiakihiro clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT shimoseshigeo clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT shironotomotake clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT sakaimiwa clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT suzukihiroyuki clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT moriyamaetsuko clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT kogahironori clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT torimuratakuji clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT kawaguchitakumi clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction AT clinicalimpactofhepaticarterialinfusionchemotherapynewfpforhepatocellularcarcinomawithpreservedliverfunction |